Pfizer: Plans For Boosters Will Not Divert Supplies From Poorer Nations
Manufacturing Output Could End Vaccine Inequity In 2022
Pfizer has pledged to supply 41% of its COVID-19 vaccine output to developing nations – but warns that these countries still need to sign contracts on time to guarantee supplies.
You may also be interested in...
South African researchers make own version of mRNA COVID-19 vaccine that uses “recipes” available in the public domain but one that is eventually expected to be “second generation” and can be more applicable to use in low- and middle-income countries. The initiative, under the wider WHO-backed mRNA vaccine technology hub, doesn’t see Moderna or BioNTech intellectual property as being a barrier.
As FDA lowers some expectations on timing of booster shots, agency’s outgoing vaccine chief says second-generation COVID vaccines may be authorized without efficacy studies. Marion Gruber's conclusion was supported by many of her international regulatory peers during a WHO meeting.
Beam is the latest allogeneic CAR-T developer to face a regulatory hold-up, but other candidates using its pioneering base-editing technology are now progressing.